New study confirms Long-Term safety of NUCALA for rare inflammatory disease
NCT ID NCT03557060
First seen Feb 01, 2026 · Last updated May 18, 2026 · Updated 14 times
Summary
This study looked at the long-term safety and effectiveness of the drug NUCALA in people with a rare disease called EGPA, which causes inflammation in blood vessels. About 300 adults who were already prescribed NUCALA for EGPA were followed for up to 2 years. Researchers tracked side effects, how well the drug controlled symptoms, and how long it took for the disease to flare up again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Tokyo, 107-0052, Japan
Conditions
Explore the condition pages connected to this study.